Specifically, the reducing microenvironment at the tumor site was exploited to reduce the GNCs precursor to a GNCs, which can form a complex with SDC1 shRNA at the tumor site to achieve targeted delivery of SDC1 shRNA at the tumor site. This evidence concerns the gene SDC1 and neoplasm.